Tofacitinib is named as a drug or biological intervention in 14 clinical trials in our China, USA, UK and India trial registers, 8 of which are recruiting. Lead sponsors include Second Affiliated Hospital, Zhejiang University, School of Medicine (3), Shanghai Zhongshan Hospital (2) and Pfizer (1). Registered phases: Phase 4, Phase 2, Phase 3, Phase EARLY_PHASE1 and Observational. Conditions studied include Ulcerative Colitis; Takayasu Arteritis; Acute Severe Ulcerative Colitis.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Ulcerative Colitis | 2 |
| Takayasu Arteritis | 2 |
| Acute Severe Ulcerative Colitis | 1 |
| Amyotrophic Lateral Sclerosis | 1 |
| Thyroid Eye Disease, TED | 1 |
| Graves Ophthalmopathy | 1 |
| Graves Orbitopathy | 1 |
| Diffuse Large B Cell Lymphoma | 1 |
| Alopecia Areata | 1 |
| Janus Kinase Inhibitors | 1 |
| Toxic Epidermal Necrolysis | 1 |
| Rheumatoid Arthritis | 1 |
| Palmoplantar Pustulosis (PPP) | 1 |
| Aneurysm | 1 |
| Behcet Syndrome, Vascular Type | 1 |
| Dermatomyositis | 1 |
| Lead sponsor | Trials |
|---|---|
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 3 |
| Shanghai Zhongshan Hospital | 2 |
| Pfizer | 1 |
| Takeda | 1 |
| Asian Institute of Gastroenterology, India | 1 |
| Beijing Tiantan Hospital | 1 |
| The First Affiliated Hospital of Xiamen University | 1 |
| Ruijin Hospital | 1 |
| Peng Zhang | 1 |
| Hangzhou Highlightll Pharmaceutical Co., Ltd | 1 |
| Peking Union Medical College Hospital | 1 |
| Register | Tofacitinib trials |
|---|---|
| Clinical trials in China | 11 |
| Clinical trials in USA | 2 |
| Clinical trials in UK | 1 |
| Clinical trials in India | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Tofacitinib works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Tofacitinib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.